Literature DB >> 11495589

Human thioredoxin reductase is efficiently inhibited by (2,2':6',2' '-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy.

K Becker1, C Herold-Mende, J J Park, G Lowe, R H Schirmer.   

Abstract

Malignant neoplasms of the brain represent the second leading cause of cancer-related mortality in children under the age of 15. The prognosis of patients with glioblastoma multiforme, the most malignant type of gliomas, remains poor offering a median survival time of only 1 year. (2,2':6',2"-Terpyridine)platinum(II) complexes are known to possess DNA-intercalating activity and have been shown to be potential chemotherapeutic agents. In the present study we identified the selenoenzyme thioredoxin reductase (TrxR) as a major target of (2,2':6',2"-terpyridine)platinum(II) complexes. New complexes were synthesized in order to optimize this inhibition. The NADPH-reduced enzyme is inhibited almost stoichiometrically by the complexes involving a reversible competitive and an irreversible tight-binding component. For the most potent inhibitor, N,S-bis(2,2':6',2"-terpyridine)platinum(II)-thioacetimine trinitrate, the K(i) for the competitive component of the inhibition is 4 nM and the IC(50) for the tight-binding component is 2 nM after an incubation time of 5 min. The closely related but non-selenium-containing enzyme glutathione reductase is much less inhibited (by a factor of >1000). The platinum complexes were found to strongly inhibit the proliferation of three different glioblastoma cell lines as well as of two different head-and-neck squamous carcinoma cell lines. In a glioblastoma cell culture, less than 10 microM of a platinum(II) compound caused an initial drop of hTrxR activity which was followed by an increase of activity in the surviving cells. A 10 microM inhibitor added every 24 h led to 4% residual hTrxR activity but 100% glutathione reductase activity in the cells surviving for 67 h. The potential of (2,2':6',2"-terpyridine)platinum(II) complexes acting simultaneously at two different intracellular targets-hTrxR and DNA-as antitumor agents is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11495589     DOI: 10.1021/jm001014i

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

1.  Glutathione reductase facilitates host defense by sustaining phagocytic oxidative burst and promoting the development of neutrophil extracellular traps.

Authors:  Jing Yan; Xiaomei Meng; Lyn M Wancket; Katherine Lintner; Leif D Nelin; Bernadette Chen; Kevin P Francis; Charles V Smith; Lynette K Rogers; Yusen Liu
Journal:  J Immunol       Date:  2012-01-25       Impact factor: 5.422

2.  DNA binding properties of novel cytotoxic gold(III) complexes of terpyridine ligands: the impact of steric and electrostatic effects.

Authors:  Pengfei Shi; Qin Jiang; Yongmei Zhao; Yangmiao Zhang; Jun Lin; Liping Lin; Jian Ding; Zijian Guo
Journal:  J Biol Inorg Chem       Date:  2006-06-09       Impact factor: 3.358

3.  Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia.

Authors:  S Talbot; R Nelson; W T Self
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

4.  Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity.

Authors:  Fei-Fei Gan; Kamila K Kaminska; Hong Yang; Chin-Yee Liew; Pay-Chin Leow; Choon-Leng So; Lan N L Tu; Amrita Roy; Chun-Wei Yap; Tse-Siang Kang; Wai-Keung Chui; Eng-Hui Chew
Journal:  Antioxid Redox Signal       Date:  2013-02-28       Impact factor: 8.401

Review 5.  Anticancer activity of metal complexes: involvement of redox processes.

Authors:  Ute Jungwirth; Christian R Kowol; Bernhard K Keppler; Christian G Hartinger; Walter Berger; Petra Heffeter
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

6.  Antioxidant enzyme inhibitor role of phosphine metal complexes in lung and leukemia cell lines.

Authors:  Burcu Saygıdeğer Demir; Tuğba Keleş; Osman Serindağ
Journal:  Bioinorg Chem Appl       Date:  2014-12-28       Impact factor: 7.778

7.  Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity.

Authors:  Victoria Hellberg; Inger Wallin; Sofi Eriksson; Emma Hernlund; Elin Jerremalm; Maria Berndtsson; Staffan Eksborg; Elias S J Arnér; Maria Shoshan; Hans Ehrsson; Göran Laurell
Journal:  J Natl Cancer Inst       Date:  2008-12-30       Impact factor: 13.506

8.  Differences in conformational dynamics of [Pt3(HPTAB)]6+-DNA adducts with various cross-linking modes.

Authors:  Yanyan Zhu; Yan Wang; Guangju Chen
Journal:  Nucleic Acids Res       Date:  2009-08-04       Impact factor: 16.971

9.  Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells.

Authors:  Karin Anestål; Stefanie Prast-Nielsen; Narimantas Cenas; Elias S J Arnér
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240

10.  Cisplatin and oxaliplatin are toxic to cochlear outer hair cells and both target thioredoxin reductase in organ of Corti cultures.

Authors:  Pascal Dammeyer; Victoria Hellberg; Inger Wallin; Göran Laurell; Maria Shoshan; Hans Ehrsson; Elias S J Arnér; Mette Kirkegaard
Journal:  Acta Otolaryngol       Date:  2014-05       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.